Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 11:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 756 matching trials from the live ClinicalTrials.gov search.
Conditions
Metastatic Colorectal Cancer (mCRC)
Interventions
Initiation of trifluridine-tipiracil plus bevacizumab, Initiation of trifluridine-tipiracil alone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Somerville, Massachusetts
Conditions
Neoplasms
Interventions
Lete-cel, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
20
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 17 more
Conditions
Neoadjuvant Treatment, Thyroid Cancer
Interventions
Zanzalintinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Cleveland, Ohio + 2 more
Conditions
Upper Tract Urothelial Carcinoma
Interventions
5-Aminolevulinic acid Hydrochloride (Gliolan®)
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Thoracic Neoplasms, Lung Neoplasms, Esophagus Neoplasms, Pleural Neoplasms, Thymus Neoplasms
Interventions
TOGA Tools
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
70 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Hematologic Disorders, Oncologic Disorders, Rheumatologic Disorders
Interventions
Rituximab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 19 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Terminated Phase 2 Interventional

ITIL-168 in Advanced Melanoma

NCT05050006
Conditions
Advanced Cutaneous Melanoma
Interventions
ITIL-168
Biological
Lead sponsor
Instil Bio
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 14 more
Conditions
Leukemia
Interventions
filgrastim, asparaginase, cyclophosphamide, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, liposomal cytarabine, mercaptopurine, mesna, methotrexate, therapeutic hydrocortisone, thiotepa, vincristine sulfate, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 20 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
62
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 48 more
Conditions
Gynecologic Disease
Interventions
Non-Interventional Study
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Pancreatic Cancer, Metastatic Pancreatic Cancer
Interventions
gemcitabine, placebo, Erlotinib, apricoxib
Drug
Lead sponsor
Tragara Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
39
States / cities
Tucson, Arizona • Bakersfield, California • Campbell, California + 36 more
Conditions
Hyperglycemia
Interventions
Insulin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Completed Phase 1Phase 2 Interventional Results available

Study of MEK162 for Children With Low-Grade Gliomas

NCT02285439
Conditions
Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms
Interventions
MEK162
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more
Terminated Not applicable Interventional Results available

RNA Precision Oncology in Advanced Pancreatic Cancer

NCT04476537
Conditions
Pancreatic Cancer
Interventions
OncoTreat
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Oncology, DIPG, DMG
Interventions
Not listed
Lead sponsor
xCures
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Altos, California
Conditions
Medical Oncology
Interventions
BAY1217389, Paclitaxel
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Santa Monica, California • Denver, Colorado • New Haven, Connecticut + 3 more
Conditions
Metastatic Solid Tumor, Advanced Solid Tumor
Interventions
CHS-114, Toripalimab, 5 Fluorouracil, Cisplatin
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
20
States / cities
Tucson, Arizona • Duarte, California • Aurora, Colorado + 16 more
Conditions
High-grade Glioma, Lung Cancer, Head & Neck Cancer, Sarcoma, Melanoma
Interventions
Fluciclatide Injection - (AH111585 (F18))
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Completed Phase 1Phase 2 Interventional Results available

AZD9291 First Time In Patients Ascending Dose Study

NCT01802632
Conditions
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Interventions
AZD9291
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 3 more
Conditions
Esophageal Cancer, Esophagogastric Junction Cancer
Interventions
Autologous genetically modified ADP-A2M4CD8 cells
Genetic
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Duarte, California • Chicago, Illinois • St Louis, Missouri + 5 more
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Supportive Care, Survey Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Hemiplegia, Brain Tumor
Interventions
Focused rigidity bi-valve long arm cast
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Locally Advanced Pancreatic Cancer, Pancreatic Cancer
Interventions
FOLFOXA
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Advanced Solid Tumors
Interventions
ALKS 4230, Pembrolizumab
Biological
Lead sponsor
Mural Oncology, Inc
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
17
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 13 more
Conditions
Stage II Lung Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
Interventions
Support for Caregiver - Generic List, Support for Caregiver - Personalized List, Internet-Based Intervention - CONNECT, Patient Navigation
Other · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
25
States / cities
Denver, Colorado • Lafayette, Colorado • Lone Tree, Colorado + 21 more